Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 18, 2026 (Event Date); September 1, 2026 (Signature Date)
Business Context: The company operates in the biodefense and vaccine sector, specifically focusing on the development and procurement of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909.
Key Financial Metrics
This filing reports a specific contract modification rather than comprehensive financial statements. Key metrics disclosed include:
- Contract Value: $24 million for additional doses of CYFENDUS.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for total revenue, net profit, operating cash flow, or margins for the period.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or liquidity positions.
Material Changes
Contract Modification: On August 18, 2026, Emergent received Modification No. 21 to its existing BARDA AV7909 Contract with the Biomedical Advanced Research and Development Authority (BARDA). This modification authorizes the procurement of additional vaccine doses valued at $24 million. This represents a material addition to the company's backlog under the long-standing agreement that became effective on September 30, 2016.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on September 1, 2026, to announce the contract modification. The filing notes that the description of the modification is qualified by reference to the full text of the agreement (Exhibit 10.1).
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard qualification that the contract description is not complete without the full text. The agreement involves government procurement, which typically carries inherent regulatory and performance risks.
Investor Verification Checklist
- Verify the specific delivery schedule and payment terms within Modification No. 21 (Exhibit 10.1).
- Confirm the total cumulative value of the BARDA AV7909 Contract including this new $24 million addition.
- Review the full text of the press release (Exhibit 99.1) for any additional strategic context regarding the anthrax vaccine program.
- Check subsequent filings for the recognition of revenue related to this modification in future quarterly reports.